Adlai Nortye’s AN4035 Receives Australian Regulatory Approvals for First-in-Class Pan-RAS(ON) ADC
Adlai Nortye (NASDAQ: ANL) announced that the company’s independently developed antibody-drug conjugate (ADC) AN4035, which...
Zai Lab’s Zocilurtatug Pelitecan Receives FDA Orphan Drug Designation for Neuroendocrine Carcinoma
Zai Lab (NASDAQ: ZLAB; HKG: 9688) announced that the US Food and Drug Administration (FDA)...
FDA Grants Biologics License to Ezplaz Freeze-Dried Plasma, First FDP Approved in United States
On July 29, 2026, the U.S. FDA granted a biologics license to Ezplaz Freeze Dried...
Novartis’ Pluvicto Receives FDA Approval for Metastatic Hormone-Sensitive Prostate Cancer
Novartis (NYSE: NVS) announced that the U.S. Food and Drug Administration (FDA) has approved Pluvicto...
HutchMed Reports H1 2026 Results with Strong Oncology Growth Despite Overall Revenue Decline
HutchMed (China) Limited (NASDAQ: HCM, HKG: 0013) announced its financial results for the six months...
Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership
Siemens Healthineers AG (ETR: SHL) and Cleveland Clinic announced the signing of a 10-year strategic...
Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership
Apeloa Pharmaceutical Co., Ltd. (SHE: 000739) announced that it has signed a Strategic Cooperation Framework...
Sansure Biotech Secures EU IVDR CE Certification for Five Nucleic Acid Diagnostic Kits
Sansure Biotech Inc. (SHA: 688289) announced that five of its nucleic acid diagnostic kits have...
Sino Biopharmaceutical’s TQB2102 Receives Breakthrough Therapy Designation from NMPA for HER2-Low Breast Cancer
Sino Biopharmaceutical Limited (HKG: 1177) announced that its subsidiary Chia Tai Tianqing Pharmaceutical (CTTQ)‘s TQB2102,...
Suzhou Forlong Biotechnology Advances FL115 Subcutaneous Injection into Phase 1 Clinical Trial for Advanced Solid Tumors
Suzhou Forlong Biotechnology Co., Ltd. announced that FL115 subcutaneous injection (administered once every three weeks)...
Shaanxi Micot Pharmaceutical Announces Positive Phase 2 Results for MT200605 in Acute Ischemic Stroke
Shaanxi Micot Pharmaceutical Technology Co., Ltd. (HKG: 2335) announced that its independently developed drug candidate...
CSPC Pharmaceutical Launches Phase Ib/II Trial of Novel SYS6090 Fusion Protein for Colorectal Cancer
CSPC Pharmaceutical Group Limited (HKG: 1093) announced that a Phase Ib/II clinical trial of SYS6090...
Sanofi Reports 17.8% Revenue Growth in Q2 2026, Driven by Dupixent and Pharma Launches
Sanofi S.A. (NASDAQ: SNY) announced second-quarter 2026 financial results, with net sales of EUR 11.6...
ELI Radiopharma and United Imaging Research Institute Forge Strategic Alliance to Advance Radiopharmaceutical Innovation
Hangzhou ELI Radiopharma Co., Ltd. (“ELI Radiopharma”) and Shanghai United Imaging Healthcare Advanced Research Institute...
NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics
China’s National Medical Products Administration (NMPA) announced that the Center for Medical Device Evaluation and...
CSPC Pharmaceutical Launches Phase II Trial of Novel ADC SYS6041 for Recurrent Ovarian Cancer in China
CSPC Pharmaceutical Group (HKG: 1093) announced that a Phase II clinical trial evaluating its self-developed...
NMPA Releases 107th Batch of Reference Drugs for Generic Quality Consistency Evaluation, Adding 71 New Specifications
China’s National Medical Products Administration (NMPA) announced the release of its 107th batch of reference...
Qyuns Therapeutics Secures NMPA Approval for QX027N Clinical Trials in COPD and CRSwNP, Announces Global Partnership
Qyuns Therapeutics Co., Ltd. (HKG: 2509) announced that its self-developed long-acting bispecific antibody, QX027N Injection,...
Jinling Pharmaceutical’s Ferric Carboxymaltose Injection Receives NMPA Acceptance for Market Authorization
Jinling Pharmaceutical Co., Ltd. (SHE: 000919) announced that the marketing authorization application for its Ferric...
Mabwell (Shanghai) Bioscience Secures NMPA Approval for 9MW5211 Clinical Trials in Primary Biliary Cholangitis
Mabwell (Shanghai) Bioscience Co., Ltd. (HKG: 2493) announced that China’s National Medical Products Administration (NMPA)...